Could a liquid form of a Graft-Versus-Host disease drug be as effective as the pill?

NCT ID NCT07726914

Not yet recruiting Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This trial compares a liquid (oral suspension) form of the drug belumosudil with the standard tablet in healthy adult men. The goal is to see if the liquid version is absorbed by the body in the same way, which could offer a more convenient option for people with chronic graft-versus-host disease. Participants take both forms at different times, and blood samples are used to measure drug levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: belumosudil (also known as Rezurock) given as an oral suspension or tablet
What this could lead to: If the liquid form works as well as the tablet, patients with chronic graft-versus-host disease may have an easier-to-swallow option.
What could go wrong: This is an early-phase study in healthy volunteers, not patients, so results may not fully predict how the liquid form performs in people with the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bronchiolitis Obliterans Syndrome chronic graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC GRAFT VERSUS HOST DISEASE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.